1. Home
  2. BNRG vs ENSC Comparison

BNRG vs ENSC Comparison

Compare BNRG & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Brenmiller Energy Ltd

BNRG

Brenmiller Energy Ltd

HOLD

Current Price

$0.53

Market Cap

2.6M

Sector

N/A

ML Signal

HOLD

Logo Ensysce Biosciences Inc.

ENSC

Ensysce Biosciences Inc.

HOLD

Current Price

$0.92

Market Cap

3.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BNRG
ENSC
Founded
2012
2003
Country
Israel
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.6M
3.1M
IPO Year
2022
N/A

Fundamental Metrics

Financial Performance
Metric
BNRG
ENSC
Price
$0.53
$0.92
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
916.1K
119.4K
Earning Date
02-27-2026
03-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$387,000.00
$4,487,973.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
843.90
1.51
52 Week Low
$0.45
$0.76
52 Week High
$12.40
$8.97

Technical Indicators

Market Signals
Indicator
BNRG
ENSC
Relative Strength Index (RSI) 36.77 37.65
Support Level $0.47 $0.76
Resistance Level $0.56 $0.95
Average True Range (ATR) 0.05 0.09
MACD 0.02 0.02
Stochastic Oscillator 51.14 47.80

Price Performance

Historical Comparison
BNRG
ENSC

About BNRG Brenmiller Energy Ltd

Brenmiller Energy Ltd is a technology company that develops, produces, markets, and sells thermal energy storage. The technology of the company allows electrification and decarbonization of the industrial industry sector for integration with renewable energy sources and further reduction of carbon emissions.

About ENSC Ensysce Biosciences Inc.

Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.

Share on Social Networks: